CorEvitas

History

2023: Thermo Fisher Scientific купил CorEvitas

On July 6, 2023, Thermo Fisher Scientific, an American manufacturer of scientific equipment, reagents, consumables and software for medical laboratories, announced an agreement to acquire CorEvitas.

CorEvitas is engaged in in-depth analysis of medical data. The firm, in particular, provides biopharmaceutical market participants with information to improve operational efficiency and improve customer service. CorEvitas manages 12 major registries of autoimmune diseases, inflammatory ailments, and pregnancy problems in the United States, Canada, and Japan. Data is collected from more than 400 research centers. CorEvitas is headquartered in Waltham, (Massachusetts).

Thermo Fisher Scientific Announces Agreement to Acquire Firm CorEvitas

The amount of the transaction between Thermo Fisher Scientific and CorEvitas is $912.5 million. It is planned to complete the transfer of assets by the end of 2023. In this case, it is necessary to obtain permits from regulatory authorities. Once the merger is complete, CorEvitas will become part of Thermo Fisher Scientific's laboratory products and biopharmaceutical services division.

The deal is expected to increase Thermo Fisher Scientific's adjusted earnings per share by $0.03 in 2024. CorEvitas has approximately 300 employees. At the end of 2023, this company expects to receive revenue in the amount of $110 million.

The inclusion of CorEvitas in our infrastructure will further enhance our pharmaceutical and biotechnology customer service capabilities. In addition, it will be possible to strengthen positions in the relevant market segment. We look forward to welcoming the CorEvitas team as part of Thermo Fisher Scientific, the buyer company said in a statement.[1]

Notes